The abstract is read at the publisher; the summary is JClub's.
FOXA2 upregulates GDF15 in metastatic clear cell renal cell carcinoma, and this FOXA2–GDF15 axis drives invasion, metastasis, and CD8+ T cell exhaustion.
- Why it matters: Metastatic ccRCC still has poor outcomes, and the molecular links between tumor spread and immune evasion—especially resistance to anti-PD-1—are not fully defined.
- What they did: The study used in vitro and in vivo functional assays, showing FOXA2 recruits HAT1 to increase GDF15, which activates GFRAL/RET–STAT3 signaling and EMT. It also tested pathway blockade with ponsegromab or pralsetinib plus anti-PD-1.
- The result: In metastatic ccRCC models, inhibiting GDF15 signaling with ponsegromab or blocking RET with pralsetinib markedly impairs FOXA2-driven metastasis and synergizes with anti-PD-1 therapy. Tumor-secreted GDF15 is linked to CD8+ T cell exhaustion in the tumor microenvironment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.